Heparin-releasing scaffold for stem cells: A differentiating device for vascular aims

Regenerative Medicine

Volumn 5, Issue 4, 2010, Pages 645-657

  Spadaccio, Cristiano ^a,c   Rainer, Alberto ^b   Centola, Matteo ^b   Trombetta, Marcella ^b   Chello, Massimo ^a   Lusini, Mario ^a   Covino, Elvio ^a   Toyoda, Yoshiya ^c   Genovese, Jorge A ^c  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b Center of Integrated Research   (Italy)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

3D scaffold; differentiation; drug release; electrospinning; heparin; poly L lactide; stem cells; tissue engineering; vascular graft

Indexed keywords

HEPARIN; MOLECULAR SCAFFOLD; POLYLACTIDE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD VESSEL GRAFT; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; ELECTROSPINNING; ENDOTHELIUM; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; PHENOTYPE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; STEM CELL;

BIOCOMPATIBLE MATERIALS; BLOOD VESSEL PROSTHESIS; BLOOD VESSELS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; DRUG DELIVERY SYSTEMS; ENDOTHELIUM, VASCULAR; HEPARIN; HUMANS; MESENCHYMAL STEM CELLS; POLYESTERS; STEM CELL TRANSPLANTATION; STEM CELLS; TISSUE ENGINEERING; TISSUE SCAFFOLDS;

EID: 77954779135     PISSN: 17460751     EISSN: None     Source Type: Journal    
DOI: 10.2217/rme.10.25     Document Type: Article

References (44)

1. Shinoka T, Shum-Tim D, Ma PX, et al.: Creation of viable pulmonary artery autografts through tissue engineering. J. Thorac. Cardiovasc. Surg. 115(3), 536-545; discussion 545-1536 (1998).
2. Shinoka T, Matsumura G, Hibino N, et al.: Midterm clinical result of tissue-engineered vascular autografts seeded with autologous bone marrow cells. J. Thorac. Cardiovasc. Surg. 129(6), 1330-1338 (2005).
3. Sarkar S, Lee GY, Wong JY, Desai TA: Development and characterization of a porous micro-patterned scaffold for vascular tissue engineering applications. Biomaterials 27(27), 4775-4782 (2006).
4. Greisler HP, Cziperle DJ, Kim DU, et al.: Enhanced endothelialization of expanded polytetrafluoroethylene grafts by fibroblast growth factor type 1 pretreatment. Surgery 112(2), 244-254; discussion 254-1245 (1992).
5. Spadaccio C, Chello M, Trombetta M, Rainer A, Toyoda Y, Genovese J: Drug releasing systems in cardiovascular tissue engineering. J. Cell. Mol. Med. 13(3), 422-439 (2009).
6. Xu C, Inai R, Kotaki M, Ramakrishna S: Electrospun nanofiber fabrication as synthetic extracellular matrix and its potential for vascular tissue engineering. Tissue Eng. 10(7-8), 1160-1168 (2004).
7. Badami AS, Kreke MR, Thompson MS, Riffle JS, Goldstein AS: Effect of fiber diameter on spreading, proliferation, and differentiation of osteoblastic cells on electrospun poly(lactic acid) substrates. Biomaterials 27(4), 596-606 (2006).
8. Hashi CK, Zhu Y, Yang GY, et al.: Antithrombogenic property of bone marrow mesenchymal stem cells in nanofibrous vascular grafts. Proc. Natl Acad. Sci. USA 104(29), 11915-11920 (2007).
9. Luong-Van E, Grondahl L, Chua KN, Leong KW, Nurcombe V, Cool SM: Controlled release of heparin from poly(e-caprolactone) electrospun fibers. Biomaterials 27(9), 2042-2050 (2006).
10. Huang ZM, Zhang ZY, Kotaki M, Ramakrishna S: A review on polymer nanofibers by electrospinning and their applications in nanocomposites. Compos. Sci. Technol. 63, 2223-2253 (2003).
11. Salacinski Hj, Tiwari A, Hamilton G, Seifalian AM: Cellular engineering of vascular bypass grafts: role of chemical coatings for enhancing endothelial cell attachment. Med. Biol. Eng. Comput. 39(6), 609-618 (2001).
12. Wight TN: Cell biology of arterial proteoglycans. Arteriosclerosis 9(1), 1-20 (1989).
13. Zilla P, Deutsch M, Meinhart J, et al.: Clinical in vitro endothelialization of femoropopliteal bypass grafts: an actuarial follow-up over three years. J. Vasc. Surg. 19(3), 540-548 (1994).
14. Rosenman JE, Kempczinski RF, Pearce WH, Silberstein EB: Kinetics of endothelial cell seeding. J. Vasc. Surg. 2(6), 778-784 (1985).
15. Spadaccio C, Rainer A, Chello M, Covino E, Trombetta M, Genovese J: Drug releasing hybrid scaffold: new avenue in cardiovascular tissue engineering. Tissue Eng. Part A 14(5), 691-943 (2008).
16. Spadaccio C, Rainer A, Trombetta M, et al.: Poly-l-lactic acid/hydroxyapatite electrospun nanocomposites induce chondrogenic differentiation of human MSC. Ann. Biomed. Eng. 37(7), 1376-1389 (2009).
17. Lobo BL, Greene WL: ACCP consensus conference on antithrombotic therapy. Indicate specific low molecular weight heparin product and dosage. Chest 110(3), 866 (1996).
18. Rawat A, Yang T, Hussain A, Ahsan F: Complexation of a poly-l-arginine with low molecular weight heparin enhances pulmonary absorption of the drug. Pharm. Res. 25(4), 936-948 (2008).
19. Sell SA, McClure MJ, Barnes CP, et al.: Electrospun polydioxanone-elastin blends: potential for bioresorbable vascular grafts. Biomed. Mater. 1(2), 72-80 (2006).
20. Smith MJ, Mcclure MJ, Sell SA, et al.: Suture-reinforced electrospun polydioxanone-elastin small-diameter tubes for use in vascular tissue engineering: a feasibility study. Acta Biomater. 4(1), 58-66 (2008).
21. Stankus JJ, Soletti L, Fujimoto K, Hong Y, Vorp DA, Wagner WR: Fabrication of cell microintegrated blood vessel constructs through electrohydrodynamic atomization. Biomaterials 28(17), 2738-2746 (2007).
22. Nieponice A, Soletti L, Guan J, et al.: Development of a tissue-engineered vascular graft combining a biodegradable scaffold, muscle-derived stem cells and a rotational vacuum seeding technique. Biomaterials 29(7), 825-833 (2008).
23. Konig G, Mcallister TN, Dusserre N, et al.: Mechanical properties of completely autologous human tissue engineered blood vessels compared with human saphenous vein and mammary artery. Biomaterials 30(8), 1542-1550 (2009).
24. Kim BS, Putnam AJ, Kulik TJ, Mooney DJ: Optimizing seeding and culture methods to engineer smooth muscle tissue on biodegradable polymer matrices. Biotechnol. Bioeng. 57(1), 46-54 (1998).
25. Soletti L, Hong Y, Guan J, et al.: A bilayered elastomeric scaffold for tissue engineering of small diameter vascular grafts. Acta Biomater. 6(1), 110-122 (2010).
26. George J, Onodera J, Miyata T: Biodegradable honeycomb collagen scaffold for dermal tissue engineering. J. Biomed. Mater. Res. A 87(4), 1103-1111 (2008).
27. Genovese JA, Spadaccio C, Langer J, Habe J, Jackson J, Patel AN: Electrostimulation induces cardiomyocyte predifferentiation of fibroblasts. Biochem. Biophys. Res. Commun. 370(3), 450-455 (2008).
28. Onodera N, Tamaki T, Okada Y, Akatsuka A, Aoki D: Identification of tissue-specific vasculogenic cells originating from murine uterus. Histochem. Cell Biol. 125(6), 625-635 (2006).
29. Jaques LB, Sue TK, Mcduffie NM, Wice SM: Heparin and sulfated mucopolysaccharides - a micro system for quantitative differentiation and determination. Can. J. Physiol. Pharmacol. 55(5), 1179-1189 (1977).
30. Yang Z, Birkenhauer P, Julmy F, et al.: Sustained release of heparin from polymeric particles for inhibition of human vascular smooth muscle cell proliferation. J. Control Release 60(2-3), 269-277 (1999).
31. Kent KC, Oshima A, Whittemore AD: Optimal seeding conditions for human endothelial cells. Ann. Vasc. Surg. 6(3), 258-264 (1992).
32. Pham QP, Sharma U, Mikos AG: Electrospinning of polymeric nanofibers for tissue engineering applications: a review. Tissue Eng. 12(5), 1197-1211 (2006).
33. Yoon JJ, Chung HJ, Lee HJ, Park TG: Heparin-immobilized biodegradable scaffolds for local and sustained release of angiogenic growth factor. J. Biomed. Mater. Res. A 79(4), 934-942 (2006).
34. Cai S, Liu Y, Zheng Shu X, Prestwich GD: Injectable glycosaminoglycan hydrogels for controlled release of human basic fibroblast growth factor. Biomaterials 26(30), 6054-6067 (2005).
35. Chung HJ, Kim HK, Yoon JJ, Park TG: Heparin immobilized porous PLGA microspheres for angiogenic growth factor delivery. Pharm. Res. 23(8), 1835-1841 (2006).
36. Casper CL, Yamaguchi N, Kiick KL, Rabolt JF: Functionalizing electrospun fibers with biologically relevant macromolecules. Biomacromolecules 6(4), 1998-2007 (2005).
37. Serizawa N, Takei Y, Okubo H, Yamasina S, Enomoto N, Sato N: Effect of low-molecular-weight heparin on the commitment of bone marrow cells to liver sinusoidal endothelial cells in CCL(4)-induced liver injury. Hepatol. Res. 34(4), 207-213 (2006).
38. Centola M, Rainer A, Spadaccio C, De Porcellinis S, Genovese J, Trombetta M: Combining electrospinning and fused deposition modeling for the fabrication of a hybrid vascular graft. Biofabrication (2010) (In Press).
39. Sank A, Wei D, Reid J, et al.: Human endothelial cells are defective in diabetic vascular disease. J. Surg. Res. 57(6), 647-653 (1994).
40. Guan J, Stankus JJ, Wagner WR: Biodegradable elastomeric scaffolds with basic fibroblast growth factor release. J. Control Release 120(1-2), 70-78 (2007).
41. Chabut D, Fischer AM, Colliec-Jouault S, et al.: Low molecular weight fucoidan and heparin enhance the basic fibroblast growth factor-induced tube formation of endothelial cells through heparan sulfate-dependent a6 overexpression. Mol. Pharmacol. 64(3), 696-702 (2003).
42. Bezuidenhout D, Davies N, Black M, Schmidt C, Oosthuysen A, Zilla P: Covalent surface heparinization potentiates porous polyurethane scaffold vascularization. J. Biomater. Appl. 24(5), 401-418 (2008).
43. Glagov S: Intimal hyperplasia, vascular modeling, and the restenosis problem. Circulation 89(6), 2888-2891 (1994).
44. Edelman ER, Nathan A, Katada M, Gates J, Karnovsky MJ: Perivascular graft heparin delivery using biodegradable polymer wraps. Biomaterials 21(22), 2279-2286 (2000).